Payment overview · 2025
General Payments
$15,393.82
46 reported records · 15 companies
Healthcare provider profile · identity verified
Renuka Sothinathan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · FAIRFAX, VA · NPI 1225124779
Verified facts
What the public records show
CMS Open Payments records show Renuka Sothinathan, M.D. received $15,393.82 in general payments during 2025 across 46 reported records.
Travere Therapeutics, Inc. accounted for 94.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14,494.95 | 94.2% | 22 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $156.65 | 1.0% | 2 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $139.64 | 0.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $120.81 | 0.8% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $118.98 | 0.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $94.17 | 0.6% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $69.99 | 0.5% | 1 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $43.70 | 0.3% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $26.83 | 0.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $25.68 | 0.2% | 1 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $25.24 | 0.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.26 | 0.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $22.77 | 0.1% | 1 | 2025 |
| NxStage Medical, Inc. | Unresolved — no canonical attribution shown | $16.62 | 0.1% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $14.53 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for serving as faculty or as a speaker for a medical education program | $8,100.00 | 4 |
| Consulting Fee | $5,000.00 | 2 |
| Food and Beverage | $1,401.94 | 36 |
| Travel and Lodging | $821.89 | 3 |
| Education | $69.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $14,432.38 | 14 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $156.65 | 2 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $139.64 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $99.09 | 5 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $69.99 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.33 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $66.33 | 2 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $43.70 | 2 | 2025 |
Source payment records
|
|||||
| Rivfloza Normalized: rivfloza |
Drug | Novo Nordisk Inc | $27.84 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $26.83 | 1 | 2025 |
Source payment records
|
|||||
| GATTEX Normalized: gattex |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| NXSTAGE SYSTEM ONE Normalized: nxstage system one |
Device | NxStage Medical, Inc. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| Gazyva Normalized: gazyva |
Biological | Genentech USA, Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Calcitriol | Calcitriol | 305 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 303 | 99 |
| Farxiga | Dapagliflozin Propanediol | 241 | 70 |
| Jardiance | Empagliflozin | 221 | 61 |
| Furosemide | Furosemide | 195 | 70 |
| Valsartan | Valsartan | 161 | 55 |
| Torsemide | Torsemide | 153 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 137 | 40 |
| Allopurinol | Allopurinol | 124 | 41 |
| Lisinopril | Lisinopril | 123 | 42 |
| Sevelamer Carbonate | Sevelamer Carbonate | 108 | 32 |
| Spironolactone | Spironolactone | 94 | 28 |
| Carvedilol | Carvedilol | 77 | 29 |
| Veltassa | Patiromer Calcium Sorbitex | 77 | 29 |
| Losartan Potassium | Losartan Potassium | 70 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 68 | 21 |
| Prednisone | Prednisone | 66 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 61 | 21 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 54 | 16 |
| Potassium Citrate Er | Potassium Citrate | 52 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 49 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 15 |
| Nifedipine Er | Nifedipine | 37 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 16 |
| Midodrine Hcl | Midodrine Hcl | 36 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | 13 |
| Cinacalcet Hcl | Cinacalcet Hcl | 33 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 29 | 14 |
| Potassium Chloride | Potassium Chloride | 29 | 17 |
| Cefdinir | Cefdinir | 27 | 16 |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Metformin Hcl | Metformin Hcl | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Calcium Acetate | Calcium Acetate | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 16 | suppressed |
| Tacrolimus | Tacrolimus | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15,393.82 · 46 records | Travere Therapeutics, Inc. | ACTHAR, FUROSCIX, Fabhalta, Filspari, GATTEX, Gazyva, IBSRELA, NXSTAGE SYSTEM ONE, Ozempic, Paradise Ultrasound Renal Denervation System, Rivfloza, Rybelsus, TARPEYO, UPLIZNA, VELPHORO, Vafseo | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error